Rallis India Q3 Results: Profit Down 54.2%
Rallis India Ltd.'s net profit was down 54.2% in the third quarter of the current financial year, missing analysts' estimates.
The profit decreased to Rs 11 crore in the quarter ended Dec. 31, 2024, according to an exchange filing on Friday. Analysts tracked by Bloomberg had pegged the profit at Rs 29 crore.
“Domestic business registered volume growth in the backdrop of intense market competition. I am pleased with the growth in biologicals and specialty solutions business, which has grown by 13%," said Gyanendra Shukla, chief executive officer and managing director, Rallis India Ltd.
Seeds business revenue was Rs 30 crore as against Rs 32 crore in the third quarter of the previous year. Exports business continues to face headwinds, with business registering a de-growth of 38%, resulting in overall revenue de-growth of 13% and drop in profitability, he said.
Rallis India Q3 FY25 Results Highlights (YoY)
Revenue down 12.71% at Rs 522 crore versus Rs 598 crore (Bloomberg estimate: Rs 628 crore).
Ebitda down 27.9% to Rs 44 crore versus Rs 61 crore.
Margin at 8.4% versus 10.2%.
Net profit down 54.2% at Rs 11 crore versus Rs 24 crore (Bloomberg estimate: Rs 29 crore).
Shares of Rallis India rose as much as 2.42% during the day to Rs 296 per share, before closing 0.21% higher at Rs 289.60 apiece on the NSE. This compared to a 0.47% decline in the benchmark Nifty 50.
The share price has risen 12.79% on a year-to-date basis.
Three of the 15 analysts tracking the company have a 'buy' rating on the stock and three suggest 'hold', with nine recommending a 'buy', according to Bloomberg data. The average of 12-month analysts' price target implies a potential upside of 13.9%.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.